How can we reduce disagreement among guidelines for venous thromboembolism prevention?
Sobieraj-Teague
M
M
Hamilton Health Sciences, Hamilton General Hospital, Hamilton, ON, Canada. teaguem@mcmaster.ca
Eikelboom
J W
JW
Hirsh
J
J
D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002370:Casts, Surgical / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019983:Guideline Adherence; D006493:Heparin / Q000627:therapeutic use; D006620:Hip Fractures / Q000601:surgery; D006801:Humans; D007717:Knee / Q000601:surgery; D035002:Lower Extremity / Q000293:injuries / Q000601:surgery; D019637:Orthopedic Procedures / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D005343:Fibrinolytic Agents; D014812:Vitamin K; D006493:Heparin; D001241:Aspirin